These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3895014)

  • 1. Desglycinamide-9-arginine-8-vasopressin (DGAVP, Organon 5667) in patients with dementia.
    Peabody CA; Thiemann S; Pigache R; Miller TP; Berger PA; Yesavage J; Tinklenberg JR
    Neurobiol Aging; 1985; 6(2):95-100. PubMed ID: 3895014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of desglycinamide-(arg8) vasopressin on memory in healthy subjects.
    Bruins J; Kumar A; Schneider-Helmert D
    Neuropsychobiology; 1990; 23(2):82-8. PubMed ID: 2077437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DGAVP (Org 5667) in early Alzheimer's disease patients: an international double-blind, placebo-controlled, multicenter trial.
    Wolters EC; Riekkinen P; Lowenthal A; Van der Plaats JJ; Zwart JM; Sennef C
    Neurology; 1990 Jul; 40(7):1099-101. PubMed ID: 2192301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical trial with desglycinamide arginine vasopressin for the treatment of memory disorders in man.
    Jennekens-Schinkel A; Wintzen AR; Lanser JB
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(3):273-84. PubMed ID: 3898228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does DGAVP influence memory, attention and mood in young healthy men?
    Snel J; Taylor J; Wegman M
    Psychopharmacology (Berl); 1987; 92(2):224-8. PubMed ID: 3110845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desglycinamide-9-arginine-8-vasopressin (DGAVP, Organon 5667) in cognitively impaired patients.
    Tinklenberg JR; Pigache R; Berger PA; Kopell BS
    Psychopharmacol Bull; 1982 Oct; 18(4):202-4. PubMed ID: 7156291
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of DGAVP on verbal memory.
    Pietrowsky R; Fehm-Wolfsdorf G; Born J; Fehm HL
    Peptides; 1988; 9(6):1361-6. PubMed ID: 3247253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effect of desglycinamide-arginine-vasopressin (DGAVP) on memory in patients with korsakoff's syndrome.
    Laczi F; Van Ree JM; Balogh L; Szász A; Járdánházy T; Wágner A; Gáspár L; Valkusz Z; Dobranovics I; Szilárd J
    Acta Endocrinol (Copenh); 1983 Oct; 104(2):177-82. PubMed ID: 6637330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial with vasopressin analogue (DGAVP) on cognitive recovery immediately after head trauma.
    Bohnen NI; Twijnstra A; Jolles J
    Neurology; 1993 Jan; 43(1):103-6. PubMed ID: 8423870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects.
    Riekkinen P; Legros JJ; Sennef C; Jolkkonen J; Smitz S; Soininen H
    Peptides; 1987; 8(2):261-5. PubMed ID: 3588346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of desmopressin on normal and impaired memory.
    Jenkins JS; Mather HM; Coughlan AK
    J Neurol Neurosurg Psychiatry; 1982 Sep; 45(9):830-1. PubMed ID: 7131017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of desglycinamide-(Arg8)-vasopressin (DGAVP) on the acquisition of free-choice alcohol drinking in rhesus monkeys.
    Kornet M; Goosen C; Ribbens LG; Van Ree JM
    Alcohol Clin Exp Res; 1991 Feb; 15(1):72-9. PubMed ID: 2024735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of DGAVP in plasma following intranasal and oral administration to healthy subjects.
    Westenberg HG; Hijman R; Wiegant VM; Laczi F; Van Ree JM
    Peptides; 1994; 15(6):1101-4. PubMed ID: 7991455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of a trimethyltin-induced learning deficit by desglycinamide-8-arginine vasopressin.
    Sparber SB; Cohen CA; Messing RB
    Life Sci; 1988; 42(2):171-7. PubMed ID: 3336276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced monoaminergic neurotransmission by desglycinamide-arginine-vasopressin in human subjects.
    Jolkkonen J; Lehtinen M; Soininen H; Sennef C; Riekkinen P
    Neurosci Lett; 1987 May; 76(3):312-5. PubMed ID: 2438607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of acute and chronic treatment with desglycinamide-[Arg8]vasopressin in young male and female volunteers.
    Bruins J; Hijman R; Van Ree JM
    Peptides; 1995; 16(2):179-86. PubMed ID: 7784246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on desglycinamide arginine vasopressin and scopolamine in a modified/lever-touch autoshaping model of learning/memory in rats.
    Mundy WR; Iwamoto ET
    Pharmacol Biochem Behav; 1987 Jun; 27(2):307-15. PubMed ID: 3628445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retention of ethanol tolerance by desglycinamide-arginine-vasopressin occurs in the absence of changes in hippocampal serotonin synthesis.
    Speisky MB; Kalant H
    Alcohol Alcohol Suppl; 1987; 1():455-9. PubMed ID: 3426715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Des-Gly9-[Arg8]-vasopressin may facilitate methadone detoxification of heroin addicts.
    van Beek-Verbeek G; Fraenkel HM; van Ree JM
    Subst Alcohol Actions Misuse; 1983; 4(5):375-82. PubMed ID: 6670060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasopressin fragment, AVP-(4-8), improves long-term and short-term memory in the hole board search task.
    Vawter MP; De Wied D; Van Ree JM
    Neuropeptides; 1997 Oct; 31(5):489-94. PubMed ID: 9413027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.